Spencer A - Search Results

1

Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.

Tam CS, Gregory GP, Ku M, Fleming S, Handunnetti SM, Lee D, Walker P, Perkins A, Lew TE, Sirdesai S, Chua CC, Gilbertson M, Lasica M, Anderson MA, Renwick W, Grigg A, Patil S, Opat S, Friebe A, Cooke R, De Boer J, Spencer A, Ritchie D, Agarwal R, Blombery P. Tam CS, et al. Among authors: spencer a. Intern Med J. 2022 Jul;52(7):1286-1287. doi: 10.1111/imj.15851. Intern Med J. 2022. PMID: 35879233 No abstract available.

2

Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.

Grigg A, Kannan K, Schwarer AP, Spencer A, Szer J. Grigg A, et al. Among authors: spencer a. Intern Med J. 2001 Jan-Feb;31(1):15-22. doi: 10.1046/j.1445-5994.2001.00013.x. Intern Med J. 2001. PMID: 11478351 Clinical Trial.

3

Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.

Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Herbert KE, et al. Among authors: spencer a. Bone Marrow Transplant. 2004 Sep;34(6):521-5. doi: 10.1038/sj.bmt.1704641. Bone Marrow Transplant. 2004. PMID: 15286686 Review.

4

A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.

Pasricha SR, Grigg A, Catalano J, Leahy M, Underhill C, Arthur C, D'Rozario J, Lowenthal R, Reed K, Spencer A. Pasricha SR, et al. Among authors: spencer a. Cancer. 2008 Dec 1;113(11):3192-8. doi: 10.1002/cncr.23915. Cancer. 2008. PMID: 18932253 Free article. Clinical Trial.

5

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, Horvath N, Roberts AW, Prince HM, Hertzberg M, McLean CA, Spencer A. Dawson MA, et al. Among authors: spencer a. Clin Cancer Res. 2009 Jan 15;15(2):714-22. doi: 10.1158/1078-0432.CCR-08-1022. Clin Cancer Res. 2009. PMID: 19147779

6

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

Dickinson M, Ritchie D, DeAngelo DJ, Spencer A, Ottmann OG, Fischer T, Bhalla KN, Liu A, Parker K, Scott JW, Bishton M, Prince HM. Dickinson M, et al. Among authors: spencer a. Br J Haematol. 2009 Oct;147(1):97-101. doi: 10.1111/j.1365-2141.2009.07837.x. Epub 2009 Aug 5. Br J Haematol. 2009. PMID: 19663825 Free article. Clinical Trial.

7

Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.

Patil S, Spencer A, Schwarer A, Avery S, Ritchie D, Opat S, Wei A, McLean C. Patil S, et al. Among authors: spencer a. Leuk Lymphoma. 2009 Dec;50(12):1964-8. doi: 10.3109/10428190903288456. Leuk Lymphoma. 2009. PMID: 19860614

8

High-dose cytarabine (24 g/m2) in combination with idarubicin (HiDAC-3) results in high first-cycle response with limited gastrointestinal toxicity in adult acute myeloid leukaemia.

Low M, Lee D, Coutsouvelis J, Patil S, Opat S, Walker P, Schwarer A, Salem H, Avery S, Spencer A, Wei A. Low M, et al. Among authors: spencer a. Intern Med J. 2013 Mar;43(3):294-7. doi: 10.1111/j.1445-5994.2012.02868.x. Intern Med J. 2013. PMID: 22757980 Review.

9

Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.

Lee D, Kalff A, Low M, Gangatharan S, Ho P, Bajel A, Ritchie D, Grigg A, Spencer A. Lee D, et al. Among authors: spencer a. Br J Haematol. 2013 Aug;162(3):371-5. doi: 10.1111/bjh.12404. Epub 2013 May 29. Br J Haematol. 2013. PMID: 23718539 Free article.

10

A single-arm, phase II study of the anti-Blys monoclonal antibody belimumab in symptomatic Waldenstrom macroglobulinemia.

Bishton M, Spencer A, Dickinson M, Ritchie D. Bishton M, et al. Among authors: spencer a. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):575-8. doi: 10.1016/j.clml.2013.04.006. Epub 2013 Jun 15. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23773449 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,612 results

Search Page